Q-omics provides the consensus-scored HNRNPDL profile across patient tissues and cancer cell-line models. HNRNPDL expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HNRNPDL is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, HNRNPDL protein abundance shows 24,985 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where HNRNPDL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPDL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPDL survival associations across molecular data types. HNRNPDL RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPDL RNA expression–survival associations across cancer types. High HNRNPDL expression shows unfavorable associations in ACC and LIHC, but favorable associations in UCS, BRCA, READ and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HNRNPDL RNA expression.
This table summarizes HNRNPDL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPDL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPDL shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in COAD, LIHC and HNSC. The COAD box plot shows higher HNRNPDL RNA expression in tumor versus normal tissue (log2 FC = +0.595, t-test p < 0.001).
This table shows molecular features associated with HNRNPDL in patient tissues and cancer cell lines. In patient samples, HNRNPDL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPDL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
